PL376021A1 - Pochodne pirolidonu jako inhibitory MAOB - Google Patents

Pochodne pirolidonu jako inhibitory MAOB

Info

Publication number
PL376021A1
PL376021A1 PL03376021A PL37602103A PL376021A1 PL 376021 A1 PL376021 A1 PL 376021A1 PL 03376021 A PL03376021 A PL 03376021A PL 37602103 A PL37602103 A PL 37602103A PL 376021 A1 PL376021 A1 PL 376021A1
Authority
PL
Poland
Prior art keywords
pyrrolidone derivatives
maob inhibitors
maob
inhibitors
pyrrolidone
Prior art date
Application number
PL03376021A
Other languages
English (en)
Other versions
PL216030B1 (pl
Inventor
Hans Iding
Synese Jolidon
Daniela Krummenacher
Rosa Maria Rodriguez-Sarmiento
Andrew William Thomas
Beat Wirz
Wolfgang Wostl
Rene Wyler
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL376021A1 publication Critical patent/PL376021A1/pl
Publication of PL216030B1 publication Critical patent/PL216030B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL376021A 2002-09-20 2003-09-18 Pochodne pirolidonu, srodek farmaceutyczny oraz zastosowanie tych pochodnych PL216030B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20

Publications (2)

Publication Number Publication Date
PL376021A1 true PL376021A1 (pl) 2005-12-12
PL216030B1 PL216030B1 (pl) 2014-02-28

Family

ID=32010924

Family Applications (3)

Application Number Title Priority Date Filing Date
PL376021A PL216030B1 (pl) 2002-09-20 2003-09-18 Pochodne pirolidonu, srodek farmaceutyczny oraz zastosowanie tych pochodnych
PL03376019A PL376019A1 (pl) 2002-09-20 2003-09-18 Pochodne pirolidonu jako inhibitory MAOB
PL03376018A PL376018A1 (pl) 2002-09-20 2003-09-18 Pochodne eteru 4-pirolidynofenylowo-benzylowego

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL03376019A PL376019A1 (pl) 2002-09-20 2003-09-18 Pochodne pirolidonu jako inhibitory MAOB
PL03376018A PL376018A1 (pl) 2002-09-20 2003-09-18 Pochodne eteru 4-pirolidynofenylowo-benzylowego

Country Status (31)

Country Link
US (4) US7151111B2 (pl)
EP (3) EP1542971A1 (pl)
JP (3) JP4335142B2 (pl)
KR (3) KR100676015B1 (pl)
CN (3) CN100503562C (pl)
AR (3) AR041298A1 (pl)
AT (2) ATE459601T1 (pl)
AU (3) AU2003267381B2 (pl)
BR (4) BR0314631A (pl)
CA (3) CA2498785C (pl)
CY (1) CY1110745T1 (pl)
DE (2) DE60331559D1 (pl)
DK (1) DK1542970T3 (pl)
ES (2) ES2344557T3 (pl)
GT (3) GT200300206A (pl)
HR (3) HRP20050263B1 (pl)
JO (2) JO2605B1 (pl)
MX (3) MXPA05002880A (pl)
MY (3) MY134480A (pl)
NO (3) NO330012B1 (pl)
NZ (3) NZ538049A (pl)
PA (3) PA8583001A1 (pl)
PE (3) PE20050077A1 (pl)
PL (3) PL216030B1 (pl)
PT (1) PT1542970E (pl)
RU (3) RU2336268C2 (pl)
SI (1) SI1542970T1 (pl)
TW (3) TWI286132B (pl)
UY (3) UY27991A1 (pl)
WO (3) WO2004026826A1 (pl)
ZA (3) ZA200501137B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY134480A (en) * 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
RU2378270C2 (ru) * 2004-08-02 2010-01-10 Ф. Хоффманн-Ля Рош Аг Бензилокси-производные в качестве ингибиторов моноаминоксидазы b
CN101128189A (zh) 2005-02-25 2008-02-20 弗·哈夫曼-拉罗切有限公司 药物物质分散性改善的片剂
MX2007011154A (es) * 2005-03-15 2007-10-17 Hoffmann La Roche Metodo para preparar derivados de eter 4-pirrolidinofenilbencilico enantiomericamente puros.
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
CA2706017A1 (en) * 2007-03-30 2008-10-09 Jorge R. Barrio In vivo imaging of sulfotransferases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
SG11201504704TA (en) 2013-03-14 2015-07-30 Dart Neuroscience Llc Substituted naphthyridine and quinoline compounds as mao inhibitors
CZ305213B6 (cs) 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
WO2015063001A1 (en) 2013-10-29 2015-05-07 F. Hoffmann-La Roche Ag Crystalline forms of a pyrrolidone derivative useful in the treatment of alzheimer's disease and preparation thereof
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
JP2018509400A (ja) * 2015-03-27 2018-04-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ セムブラギリンを含む医薬製剤
JP7169592B2 (ja) 2017-09-27 2022-11-11 国立大学法人 鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた鎮痛薬
JP2020536870A (ja) 2017-10-05 2020-12-17 バイオジェン インコーポレイテッド アルファカルボキサミドピロリジン誘導体の調製方法
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
US11225460B2 (en) 2018-03-08 2022-01-18 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
EP3932490B1 (en) 2019-02-27 2025-04-02 Kagoshima University Antipruritic agent using pac1 receptor antagonist
EP4147701A4 (en) 2020-05-08 2024-06-12 Kagoshima University Antidepressant/anxiolytic drug in which pac1 receptor antagonist is used
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
DE69025418T2 (de) 1989-04-19 1996-11-14 Otsuka Pharma Co Ltd Phenylcarbonsäurederivate mit einem Heterocyclus
ATE253057T1 (de) * 1994-08-30 2003-11-15 Sankyo Co Isoxazole
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
WO1997033572A1 (en) 1996-03-15 1997-09-18 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neurophathy by administering selegiline
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
EP1165546A2 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
ATE306233T1 (de) * 2000-02-10 2005-10-15 Potencia Medical Ag Behandlung der harninkontinenz mit kabelloser energiezufuhr
EP1255513B1 (en) * 2000-02-14 2005-05-25 Potencia Medical AG Penile prosthesis
MY134480A (en) * 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism

Also Published As

Publication number Publication date
AU2003273901A1 (en) 2004-04-08
JP4335141B2 (ja) 2009-09-30
DK1542970T3 (da) 2010-08-02
BR0314314A (pt) 2005-07-26
AU2003270213B8 (en) 2009-03-05
AU2003267381B2 (en) 2009-08-27
ZA200501137B (en) 2006-12-27
CN100383118C (zh) 2008-04-23
NO330012B1 (no) 2011-02-07
KR20050057466A (ko) 2005-06-16
MXPA05002880A (es) 2005-05-27
CA2496756C (en) 2012-01-10
HRP20050263B1 (hr) 2013-09-30
RU2005111974A (ru) 2006-01-20
NO20050665L (no) 2005-04-18
PL376019A1 (pl) 2005-12-12
CY1110745T1 (el) 2015-06-10
ZA200501311B (en) 2006-10-25
PE20050077A1 (es) 2005-03-01
RU2005111969A (ru) 2006-01-20
US7122562B2 (en) 2006-10-17
US20040106650A1 (en) 2004-06-03
TW200410935A (en) 2004-07-01
RU2323209C2 (ru) 2008-04-27
CN1681778A (zh) 2005-10-12
PA8583501A1 (es) 2004-04-23
AR041297A1 (es) 2005-05-11
JP2006503833A (ja) 2006-02-02
JP2006510596A (ja) 2006-03-30
NZ538049A (en) 2007-05-31
KR20050057450A (ko) 2005-06-16
GT200300205A (es) 2004-04-29
MY135696A (en) 2008-06-30
CA2498785C (en) 2011-07-26
PA8583601A1 (es) 2004-09-16
US7235581B2 (en) 2007-06-26
UY27993A1 (es) 2004-03-31
RU2336267C2 (ru) 2008-10-20
PE20050079A1 (es) 2005-03-01
TW200413350A (en) 2004-08-01
KR20050057456A (ko) 2005-06-16
MY134480A (en) 2007-12-31
US7037935B2 (en) 2006-05-02
DE60331559D1 (de) 2010-04-15
AR041299A1 (es) 2005-05-11
DE60333202D1 (de) 2010-08-12
HRP20050262A2 (en) 2006-06-30
US20040097578A1 (en) 2004-05-20
CA2498335A1 (en) 2004-04-01
US20060122235A1 (en) 2006-06-08
KR100676014B1 (ko) 2007-01-30
ES2344557T3 (es) 2010-08-31
EP1542969B1 (en) 2010-03-03
EP1542970A1 (en) 2005-06-22
AU2003267381A1 (en) 2004-04-08
NZ538048A (en) 2007-05-31
TWI331994B (en) 2010-10-21
HK1083499A1 (zh) 2006-07-07
BR0314299A (pt) 2005-12-13
ES2338646T3 (es) 2010-05-11
AU2003270213A1 (en) 2004-04-08
JO2604B1 (en) 2011-11-01
HK1084383A1 (en) 2006-07-28
KR100676015B1 (ko) 2007-01-30
GT200300204A (es) 2004-04-29
ATE459601T1 (de) 2010-03-15
NO20050701L (no) 2005-03-02
PL376018A1 (pl) 2005-12-12
WO2004026827A1 (en) 2004-04-01
MXPA05002878A (es) 2005-05-27
UY27991A1 (es) 2004-03-31
US7151111B2 (en) 2006-12-19
CN1681779A (zh) 2005-10-12
PE20050078A1 (es) 2005-02-28
NO329754B1 (no) 2010-12-13
PT1542970E (pt) 2010-07-19
TWI286132B (en) 2007-09-01
KR100681586B1 (ko) 2007-02-09
WO2004026826A1 (en) 2004-04-01
NO20050652L (no) 2005-03-08
MY133332A (en) 2007-11-30
JP2006503834A (ja) 2006-02-02
AU2003270213B2 (en) 2009-02-12
BR0314631A (pt) 2005-08-02
JP4335140B2 (ja) 2009-09-30
JO2605B1 (en) 2011-11-01
BRPI0314631B1 (pt) 2018-04-17
RU2336268C2 (ru) 2008-10-20
WO2004026825A1 (en) 2004-04-01
HRP20050263A2 (en) 2006-12-31
SI1542970T1 (sl) 2010-08-31
RU2005111968A (ru) 2006-11-10
AR041298A1 (es) 2005-05-11
ATE472530T1 (de) 2010-07-15
CN1681777A (zh) 2005-10-12
CN100503562C (zh) 2009-06-24
TW200408624A (en) 2004-06-01
TWI337604B (en) 2011-02-21
ZA200501557B (en) 2005-09-08
NZ538046A (en) 2007-08-31
EP1542970B1 (en) 2010-06-30
PA8583001A1 (es) 2004-04-23
JP4335142B2 (ja) 2009-09-30
UY27990A1 (es) 2004-03-31
EP1542969A1 (en) 2005-06-22
HRP20050261A2 (en) 2006-05-31
CA2498785A1 (en) 2004-04-01
CN100400509C (zh) 2008-07-09
US20040116707A1 (en) 2004-06-17
CA2496756A1 (en) 2004-04-01
HK1083498A1 (zh) 2006-07-07
EP1542971A1 (en) 2005-06-22
AU2003273901B2 (en) 2008-07-10
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
GT200300206A (es) 2004-04-29

Similar Documents

Publication Publication Date Title
ZA200501137B (en) Pyrrolidone derivatives as MAOB inhibitors
EG25482A (en) Inhibitors
IL173616A0 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
SI1492785T1 (sl) 2-hidroksi-3-heteroarilindolni derivati kot inhibitorji GSK3
AU2003201850A1 (en) N-alkylsulfonyl-substituted amide derivatives
AU2003300832A8 (en) Nf-kappab inhibitors
GB0315870D0 (en) Heterocyclic derivatives
EP1532133A4 (en) NF-: B INHIBITORS
AU2003230392A8 (en) Beta-secretase inhibitors
AP1963A (en) Substituted pyrrole derivatives and their use as HMG-co inhibitors
IL180791A0 (en) Benzyloxy derivatives as maob inhibitors
GB2403474B (en) Amide derivatives
AU2003224941A8 (en) Nf-kappab inhibitors
AU2003235889A8 (en) Amide derivatives
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
GB2388841B (en) Polymerisable heterocyclic acetylenes
GB0226609D0 (en) Heterocyclic derivatives
GB0311957D0 (en) Heterocyclic derivatives
HRP20050156A2 (en) Pyrrolidine derivatives as tryptase inhibitors
IL169094A0 (en) 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors
HK1091765A (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
GB0207491D0 (en) Inhibitors
GB0206031D0 (en) Inhibitors
GB0207488D0 (en) Inhibitors
GB0226149D0 (en) Inhibitors

Legal Events

Date Code Title Description
RECP Rectifications of patent specification
RECP Rectifications of patent specification